EcoDrugPlus

Nischarin

Ensembl ID : ENSXETG00000021467
Gene Symbol: NISCH
6 Enzyme and pathways 5 View Cross-references
209 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nitric Oxide Synthase 2

Ensembl ID : ENSXETG00000012498
Gene Symbol: NOS2
8 Enzyme and pathways 5 View Cross-references
165 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Notch 1 Receptor

Ensembl ID : ENSXETG00000000757
Gene Symbol: NOTCH1
5 View Cross-references
270 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Notch 3

Ensembl ID : ENSXETG00000002570
Gene Symbol: NOTCH3
5 View Cross-references
199 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B-Cells 1

Ensembl ID : ENSXETG00000021325
Gene Symbol: NFKB1
54 Enzyme and pathways 5 View Cross-references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B-Cells 2

Ensembl ID : ENSXETG00000000013
Gene Symbol: NFKB2
43 Enzyme and pathways 5 View Cross-references
124 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Receptor Subfamily 1 Group H Member 2

Ensembl ID : ENSXETG00000000307
Gene Symbol: NR1H2
5 View Cross-references
304 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSXETG00000030372
Gene Symbol: NR1H4
21 Enzyme and pathways 5 View Cross-references
387 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSXETG00000042129
Gene Symbol: NR3C1
12 Enzyme and pathways 5 View Cross-references
278 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSXETG00000026061
Gene Symbol: NR3C2
5 View Cross-references
212 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nucleoplasmin Atpase-Like

Ensembl ID : ENSXETG00000030790
Gene Symbol: XB5867546
8 Enzyme and pathways 3 View Cross-references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Opioid Receptor Delta 1

Ensembl ID : ENSXETG00000033842
Gene Symbol: OPRD1
7 Enzyme and pathways 5 View Cross-references
252 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).